Evidence map›Paper›PMID 36104197›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Triple-negative Thrombocythemia and Subsequent Acute Lymphoblastic Leukemia with Additional Somatic Mutations.

Yuri Tsuboi, Tatsuhiro Sakamoto, Kenichi Makishima, Yasuhito Suehara, Keiichiro Hattori, Naoki Kurita, Yasuhisa Yokoyama, Takayasu Kato, Hidekazu Nishikii, Naoshi Obara and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Yuri TsuboiDepartment of Hematology, University of Tsukuba Hospital, Japan.
Tatsuhiro SakamotoDepartment of Hematology, University of Tsukuba Hospital, Japan.
Kenichi MakishimaDepartment of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Japan.
Yasuhito SueharaDepartment of Hematology, University of Tsukuba Hospital, Japan.
Keiichiro HattoriDepartment of Hematology, University of Tsukuba Hospital, Japan.
Naoki KuritaDepartment of Hematology, University of Tsukuba Hospital, Japan.
Yasuhisa YokoyamaDepartment of Hematology, University of Tsukuba Hospital, Japan.
Takayasu KatoDepartment of Hematology, University of Tsukuba Hospital, Japan.
Hidekazu NishikiiDepartment of Hematology, University of Tsukuba Hospital, Japan.
Naoshi ObaraDepartment of Hematology, University of Tsukuba Hospital, Japan.
Fumiaki MatsumuraDepartment of Hematology, University of Tsukuba Hospital, Japan.
Ryota MatsuokaDepartment of Pathology, Faculty of Medicine, University of Tsukuba, Japan.
Shigeru ChibaDepartment of Hematology, University of Tsukuba Hospital, Japan.
Mamiko Sakata-YanagimotoDepartment of Hematology, University of Tsukuba Hospital, Japan.
University of Tsukuba Hospital · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative essential thrombocythemia (ET) is a condition in which mutations in JAK2, CALR and MPL are all negative. Transformation to acute myeloid leukemia may occur during the course of ET, while B-acute lymphoblastic leukemia B-(ALL) is rare. We experienced a case diagnosed as B-ALL during the course of triple-negative ET. Notably, cytoreduction was required for the excessive increase in blood cells during the bone marrow recovery period after chemotherapies. Whole exome sequencing identified 17 somatic mutations: 9 were identified in both ET and B-ALL samples, while 8 were specific to B-ALL, suggesting that these 8 might have caused the transformation.

Indexed as

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaThrombocythemia, EssentialCalreticulinHumansJanus Kinase 2MutationCalreticulinJanus Kinase 2B-acute lymphoblastic leukemiaclonal evolutiontriple-negative essential thrombocythemia

Identifiers

PMID36104197
PMCPMC10258111
OpenAlexW4295909081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.